bluuebunny/crossref_metadata_2025 huggingface dataset:
Abstract 6781: Spatial omics using spatially-resolved laser-activated cell sorting for cancer biomarker discovery
Authors: Lee Amos C. , Lee Sumin , Kwon Sunghoon
Published: April 2023

Cancer is spatially heterogeneous in terms of genetic molecules. Revealing genomic, epigenomic, transcriptomic, and epitranscriptomic features that are unique to the malignant cell populations within cancer lead to cancer biomarker discoveries that can be translated into diagnostic or therapeutic tools. Here, we introduce spatially-resolved laser-activated cell sorting (SLACS) technology coupled to next generation sequencing and mass spectrometry that analyzes genetic molecules from regions of interest within spatial context. Specifically, we demonstrate application of SLACS in various cancers such as breast cancer, glioblastoma, glioma, meningioma, multiple myeloma, and leukemia. Examples of discovering cancer biomarker and their mechanism of action within spatial context are also provided. Specifically, we describe Select-seq which isolates the regions of interest as small as single cells from the immunofluorescence stained tissue and obtains the full-length transcriptome data. We demonstrated Select-seq on tumor tissue section from triple negative breast cancer patient who have received neoadjuvant chemotherapy. Select-seq produced full-length spatial transcriptome data, with which we analyzed the transcriptomic and epitranscriptomic features including alternative splicing variant, complementarity-determining region analysis of B cells, and even adenosine-to-inosine base editing. We were also able to analyze the immune- and stem-cell-like microniches, in which the complex mechanisms behind ferroptosis inhibition might suggest therapeutic options for the TNBC patients. Bridging spatial technologies to omics technologies, the discovery of specific markers within spatial context will provide insights into the next generation diagnostics and cancer therapeutics such as cancer vaccines.

Citation Format: Amos C. Lee, Sumin Lee, Sunghoon Kwon. Spatial omics using spatially-resolved laser-activated cell sorting for cancer biomarker discovery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6781.
Abstract 6796: PoxSTG, a novel chimeric poxvirus with improved oncolytic potency
Authors: Erbs Philippe , Findeli Annie , Foloppe Johann , Kempf Juliette , Farine Isabelle , Moreau Baptiste , Hortelano Julie , Pichon Christelle , Deforges Jules , Quemeneur Eric
Published: April 2023

Oncolytic virus (OV) therapy has emerged as a promising approach for cancer treatment with the potential to be less toxic and more efficient than classic cancer therapies. Various types of OVs in clinical development, including Vaccinia virus (VACV)-derived OVs, have shown good safety profiles, but limited therapeutic efficacy as monotherapy in some cancer models. Many different methods have been employed to improve the oncolytic potency of OVs. We used a directed evolution process, pooling multiple species of orthopoxviruses to generate chimeric poxviruses with increased oncolytic properties. Through selective pressure by successive passages on human tumor cells, a new chimeric oncolytic poxvirus, named PoxSTG, was derived. The chimeric viral genome contains, in addition to sequences from several strains of Vaccinia virus, sequences of Rabbitpox virus and Cowpox virus. Compared with its parental viruses, PoxSTG has demonstrated superior oncolytic characteristics, and was notably attenuated in normal primary cells. PoxSTG has superior secretion of extracellular-enveloped virus (EEV) compared to all parental strains inducing higher dissemination of the virus into the tumors and more resistance to neutralization. PoxSTG was saved and showed potent antitumor effects in several syngeneic and xenograft mouse models of cancers. Furthermore, PoxSTG exerted low-dose antitumor effects in virus-injected and non-virus-injected distant tumors in a CRC xenograft model, demonstrating strong virus spread to distant tumors. All these data demonstrate the potential of PoxSTG as a novel therapeutic agent for cancer treatment.

Citation Format: Philippe Erbs, Annie Findeli, Johann Foloppe, Juliette Kempf, Isabelle Farine, Baptiste Moreau, Julie Hortelano, Christelle Pichon, Jules Deforges, Eric Quemeneur. PoxSTG, a novel chimeric poxvirus with improved oncolytic potency. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6796.
Abstract 683: Vaccination against androgen receptor splice variant induces anti-tumor adaptive immune responses
Authors: Marek Robert D. , Wei Junping , Wang Tao , Yang Xiao-Yi , Lei Gangjun , Hartman Zachary C.
Published: April 2023

Background: Androgen receptor (AR) signaling has been the central target for standard-of-care prostate cancer therapies, although de novo resistance to these therapies occurs in many metastatic prostate cancer patients within 2-3 years. Resistance to AR targeting agents most often develops through overexpression of AR and expression of truncated, constitutively active RNA splice variants of AR. While clinical use of PD-1/PD-L1 immune checkpoint blockade has failed to demonstrate clinical success in treating resistance prostate cancers, the slower progression of prostate cancer provides an opportunity for immune targeted interventions. Cancer specific vaccines have the potential to enable and enhance tumor specific immune responses by stimulating and directing T cell immunity to important oncologic targets. We hypothesized that a cancer vaccine designed to induce a T cell response against cells expressing high levels of AR would result in an anti-tumor effect and potentially prevent or delay the development of therapeutic resistance.

Methods: To evaluate AR and AR variants as potential immunological targets, we produced adenoviral vaccines against AR (Ad-AR) or AR splice variant 7 (Ad-AR-V7). We vaccinated naïve mice and examined AR and AR variant specific immunity in peptide restimulation. We further tested our vaccines in prophylactic and therapeutic regimens using multiple subcutaneous syngeneic tumor models (including prostate tumor lines, such as TrampC2) which were engineered to express AR or AR-V7.

Results: Adenoviral vaccines targeting AR or AR-V7 produced robust T-cell responses against the N-terminal domain of AR. Notably, vaccination with both Ad-AR or Ad-AR-V7 induced significant anti-tumor immune responses, inducing complete tumor clearance against tumors expressing AR-V7 and allowing for long-term survival in the majority of vaccinated mice.

Conclusions: These data demonstrate the potential of AR and AR splice variants as immunologic targets of prostate cancer vaccines, which elicit AR specific T cell immunity and produce anti-tumor responses in prostate cancers.

Citation Format: Robert D. Marek, Junping Wei, Tao Wang, Xiao-Yi Yang, Gangjun Lei, Zachary C. Hartman. Vaccination against androgen receptor splice variant induces anti-tumor adaptive immune responses [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 683.
Abstract 707: High major histocompatibility complex class I expression overcomes cancer immunotherapy resistance due to interferon gamma signaling pathway defects
Authors: Kawase Katsushige , Kawashima Shusuke , Nagasaki Joji , Inozume Takashi , Yamamoto Hiromasa , Kawazu Masahito , Hanazawa Toyoyuki , Togashi Yosuke
Published: April 2023

IFN-γ signaling pathway defects such as JAK mutations are well-known mechanisms of resistance to immune checkpoint inhibitors (ICIs). However, some patients respond to ICIs despite IFN-γ signaling pathway defects, and the detailed mechanisms remain unclear. Here, we created JAK-deleted cancer cell lines and evaluated antitumor immunity. As a result, several tumors responded to PD-1 blockade despite JAK deletion. Such sensitive tumors had high major histocompatibility complex class I (MHC-I) expression despite IFN-γ signaling pathway defects, whereas MHC-I expression was reduced by JAK deletion in resistant tumors. In particular, if cancer cells had high MHC-I expression despite defects in IFN-γ signaling pathways, chemokines that recruit effector T cells were mainly produced by immune cells rather than cancer cells in the tumor microenvironment. Accordingly, we found a response to ICIs in a patient with JAK-negative head and neck squamous cell carcinoma, whose human leukocyte antigen class I (HLA-I) expression level was maintained. In addition, clustered regularly interspaced short palindromic repeats (CRISPR) screening to identify molecules with elevated MHC-I expression independent of IFN-γ signaling pathways demonstrated that guanine nucleotide-binding protein subunit gamma 4 (GNG4) maintained MHC-I expression via the NF-κB signaling pathway. Our results indicate that patients with IFN-ɤ signaling pathway defects are not always resistant to ICIs, and highlight the importance of MHC-I expression among the pathways, including inhibitory effects on cellular proliferation or chemokine production, and the possibility of NF-κB-targeted therapies to overcome such resistance.

Citation Format: Katsushige Kawase, Shusuke Kawashima, Joji Nagasaki, Takashi Inozume, Hiromasa Yamamoto, Masahito Kawazu, Toyoyuki Hanazawa, Yosuke Togashi. High major histocompatibility complex class I expression overcomes cancer immunotherapy resistance due to interferon gamma signaling pathway defects [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 707.
Abstract 71: Melanoma alters the bone marrow immune composition in an age-related manner
Authors: Carey Alexis Erasta , Chhabra Yash , Black Ethan , Rocha Murilo Ramos , Fane Mitchell , Wang Vania , Zabransky Daniel , Bravante Gloria , Hueser Laura , Weeraratna Ashani
Published: April 2023

Melanoma accounts for the most skin cancer-related deaths in the United States. As patients age, anti-tumor responses decline, making age a negative independent prognostic factor of overall survival in melanoma. Despite advances in immunotherapeutic modalities, there remains a subset of patients who do not benefit from these treatments. Understanding cancer and age-related changes to immune cell development in the bone marrow can improve patient outcomes. We hypothesize that during aging, the bone marrow niche is reshaped, driving precursor cells to become immunosuppressive. This ultimately decreases the anti-tumor response to melanoma due to the skewing of hematopoiesis to yield decreased immune function. In order to tackle this hypothesis, flow cytometry was used to analyze immune compositional changes in the bone marrow of mice challenged with melanoma. Our preliminary data suggests that when melanoma is present in the skin, there are changes to the bone marrow niche, such as an increase in total myeloid cells. Specifically, in the bone marrow of aged tumor-bearing mice, we see a decrease in Ly6C+Ly6G+ granulocytic progenitor cells and an increase in Ly6C+Ly6G- monocytic progenitor cells compared to the bone marrow of young tumor-bearing mice. We predict that the secretome of the aged bone marrow niche will impact immune cell development by producing more immature myeloid cells that can travel to the tumor site. We also saw an increase in the proportion of CD4+ T-cells in the aged bone marrow when melanoma is present. Thus, there appears to be a shift in cell populations in the aged bone marrow niche when the mice are burdened with melanoma. As a future direction, we plan to investigate the role of the aged bone marrow niche and its secretome on the effectiveness of immunotherapies, such as anti-PD-1. These insights could lead to improved outcomes for elderly patients with melanoma.

Citation Format: Alexis Erasta Carey, Yash Chhabra, Ethan Black, Murilo Ramos Rocha, Mitchell Fane, Vania Wang, Daniel Zabransky, Gloria Bravante, Laura Hueser, Ashani Weeraratna. Melanoma alters the bone marrow immune composition in an age-related manner [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 71.
Abstract 993: Epigenetic immune cell profiling in B-non-Hodgkin lymphoma biopsies
Authors: Werner Jeannette , Walter Steffi , Sachsenmaier Christoph , Schulze Janika , Phippard Deborah , Olek Sven , Seliger Barbara , Wickenhauser Claudia
Published: April 2023

Early detection and differential diagnosis of Non-Hodgkin lymphoma (NHL) is essential for the initiation of suitable therapy options. Biopsy based diagnosis allows allocation to World Health Organization (WHO) sub-classification groups but prognosis often needs identification of specific genetic aberrations or gene expression patterns. Despite this strategy, prognosis is difficult, since diseases, like e.g. mantel cell lymphoma, can be indolent or aggressive. Here we report the characterization of NHL biopsies using epigenetic immune cell quantification. This approach is based on the identification of specifically demethylated regions in individual immune cell types. These regions are then quantified using methylation-sensitive qPCR after bisulfite conversion. This highly reproducible and objective method allows in depth immunophenotyping of the tumor microenvironment. Next to CD4+ and CD8+ T cells, B cells and NK cells more specialized immune cells like regulatory T cells (Tregs), follicular T helper cells, PD-1 expressing cells and Myeloid derived suppressor cells (MDSC) were quantitatively determined in formalin-fixed tissue samples of 251 patients with different B cell Non-Hodgkin lymphomas. As a result, characteristic immune cell distribution patterns were identified for the different lymphoma entities, including chronic lymphocytic leukemia (B-CLL) (n=41), mantle cell lymphoma (MCL) (n=32), follicular lymphoma (FL) (n=33), diffuse large B cell lymphoma (DLBCL) (n=74), marginal zone lymphoma (MZL) (n=40) and B cell acute lymphoblastic leukemia (B-ALL) (n=26). In addition, substantial heterogeneity within the entities was observed that may correlate with disease prognosis. Among others, this is particularly the case for MDSC in B-CLL patients as well as for NK cells and Tregs in MCL and PD-1+ cells in FL patients. Currently clusters within the different disease groups are analyzed with regard to the clinical outcome to investigate if disease prognosis can be predicted by epigenetic immune cell quantification. In conclusion, epigenetic immune cell quantification is a suitable method to analyze the tumor microenvironment of NHL patients with the potential to support patient’s prognosis.

Citation Format: Jeannette Werner, Steffi Walter, Christoph Sachsenmaier, Janika Schulze, Deborah Phippard, Sven Olek, Barbara Seliger, Claudia Wickenhauser. Epigenetic immune cell profiling in B-non-Hodgkin lymphoma biopsies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 993.
Abstract 995: Evaluation of plasma cytokines and chemokines as potential biomarkers for colorectal cancer detection
Authors: Caraballo Elba V. , Centeno-Girona Hilmaris , Macias Yilda , Ocasio Madeline M. Mártir , Cruz-Correa Marcia R.
Published: April 2023

Despite evidence suggesting that current Colorectal Cancer (CRC) screening strategies reduce mortality rates, screening compliance is suboptimal; for this, our study aimed to evaluate the discriminatory potential of plasma cytokine and chemokine levels for CRC detection in plasma samples in a Hispanic subpopulation. Using a retrospective case-control study design, we evaluated plasma samples in 20 CRC cases and 20 age-gender matched controls from the Puerto Rico Familial Colorectal Cancer Registry (PURIFICAR). BD CBA Human Th1/Th2/Th17 Cytokine and Human Chemokine kits were used to prepare plasma samples for flow cytometric analysis (Becton-Dickinson & Co). Mann-Whitney-U test was used to detect differences between biomarkers and case-control groups. Measures of diagnostic accuracy were estimated for comparisons according to CRC disease stage. We compared multivariable models to determine the best CRC case-classifier. The median levels of six of the cytokines evaluated (IL-2, IL-4, IL-6, IL-10, TNF, and IL-17A) and one chemokine (CXCL10-/IP-10) significantly differed between cases and controls (P<0.05). ROC plots and logistic regression analysis showed that these seven biomarkers displayed good to excellent accuracy (AUC: 0.6-0.9). Multivariate analysis showed that the best-case classifying model included the seven statistically significant markers. Our findings suggest that discriminatory biomarker levels between CRC cases and controls observed show their great potential as targets in novel blood-based screening tests for CRC. The development of a non-invasive CRC screening test will provide an alternative to increasing adherence, early detection, survivorship, and a tool for a population-based prevention strategy approach.

Citation Format: Elba V. Caraballo, Hilmaris Centeno-Girona, Yilda Macias, Madeline M. Mártir Ocasio, Marcia R. Cruz-Correa. Evaluation of plasma cytokines and chemokines as potential biomarkers for colorectal cancer detection [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 995.
Abstract PL03-02: When to intervene along the breast cancer continuum?
Authors: Hwang E. Shelley
Published: April 2023

Advances in epidemiology and cancer biology have clearly established that the group of diseases currently deemed “cancers” in fact encompasses many conditions with enormous variation in biologic behavior. Decades of cancer screening have preferentially diagnosed early, asymptomatic, indolent lesions. This trend will only increase as screening technologies become ever more sensitive, leading to an epidemic of overtreatment in completely asymptomatic individuals. The treatment of many of these conditions often has uncertain benefit on cancer mortality, while coming at the clear cost of treatment-related morbidity. Multi-omic testing plays a role in refining treatment recommendations based upon risk of progression. Genomic profiling of accurately annotated longitudinal case control datasets have provided insights into breast lesions termed “ductal carcinoma in situ” (DCIS), which are thought to be precursors to invasion and metastases. Both transcriptomics as well spatially resolved proteomic characterization of DCIS have uncovered novel biology of the epithelial cells that make up DCIS, as well as the heterogeneous precancer ecosystems which can be either permissive or inhibitory for invasion. Recent work has uncovered a clonal evolution pathway characterized by multiclonal invasion, and has helped to build risk stratification tools to refine treatment recommendations. In addition to molecular characterization, risk modeling may yield insights about which patients derive greatest benefit from intervention. For asymptomatic tumors at low risk of cancer progression, there may be little to no benefit to treatment, whereas for more high-risk lesions, progression to invasion and metastasis may be rapid and deadly. Given the lead-time between the development of precancer and progression to invasive disease, there may also be a case for tailoring intervention of screen detected cancer by age and the presence of competing comorbidities. The decision of whether and when to intervene for screen-detected cancers will require a multidisciplinary effort including expertise in cancer biology, mathematical modeling, psychology, health policy, decision science and communication, as well as thoughtful engagement from patients and health care providers to identify the optimal time to intervene along the cancer progression continuum.

Citation Format: E. Shelley Hwang. When to intervene along the breast cancer continuum?. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr PL03-02.
Abstract PL03-04: Forecasting pancreatic carcinogenesis through spatial multi-omics
Authors: Fertig Elana Judith
Published: April 2023

This talk presents a hybrid computational and experimental strategy to uncover interactions between neoplastic cells and the microenvironment during pancreatic carcinogenesis. As pancreatic cancer develops, it forms a complex microenvironment of multiple interacting cells. The microenvironment of advanced pancreatic cancer includes a dense composition of cells, such as macrophages and fibroblasts, that are associated with immunosuppression. New single-cell and spatial molecular profiling technologies enable unprecedented characterization of the cellular and molecular composition of the microenvironment. These technologies provide the potential to identify candidate therapeutics to intercept immunosuppression in pancreatic cancer. Inventing new mathematical approaches in computational biology are essential to uncover mechanistic insights from high-throughput data for these precision interception strategies. Here, we demonstrate how converging technology development, machine learning, and mathematical modeling can relate the pancreatic precancer microenvironment to carcinogenesis and therapeutic response. Combining genomics with mathematical modeling provides a forecast system that can yield computational predictions to anticipate when and how the cancer is progressing for therapeutic selection. This mathematical forecast system will empower a new predictive oncology paradigm, which selects therapeutics to intercept the pathways that would otherwise cause future cancer progression.

Citation Format: Elana Judith Fertig. Forecasting pancreatic carcinogenesis through spatial multi-omics. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr PL03-04.
Abstract PL05-02: To the tumor and beyond: Tales of a holistic miRNA delivery vehicle
Authors: Kasinski Andrea L.
Published: April 2023

Like the challenges and skepticism that faced the antibody therapeutics field over a decade ago, RNA therapeutics is facing the same. And, like the antibody therapeutics field, we are beginning to realize the clinical impact of RNA therapeutics amiss these challenges. This is most clearly highlighted with the recent approval of mRNA vaccines to prevent against SARS-CoV-2 and the first FDA approved RNAi drugs targeted to the liver. Unfortunately, RNA-based drugs targeted to cancer cells is lagging behind, even with countless years of work that has revealed the power of using RNAi for treating oncological diseases. Lack of success in this space is attributed to inability to deliver RNAi safely and effectively. A successful delivery agent requires multiple features. First, the agent must deliver the RNA specifically to the intended cells. Second, the agent must have a large therapeutic window, meaning that toxicity, if observed, should occur at doses that are orders of magnitude higher than the therapeutic dose. Third, if delivery of the RNA is by way of a specific ligand and receptor pair, as is the case herein, the RNA must successfully escape the endosome. Simply swelling the endosome is not enough if noncovalent interactions between the ligand and the receptor cannot be disrupted. Fourth, the RNA should include appropriate stabilizing modifications to increase intracellular half-life that will reduce dosing and cost. Through hard work and dedication in this space, we have come up with an inclusive, easily synthesized, intramolecular molecule that achieves all of these essential features. Moreover, the ligand used to achieve successful delivery is also being evaluated for imaging tumors localized in the central nervous system. Here, the challenges we face, the hurdles we have overcome, and the barriers that still remain to achieve success in revealing the clinical potential of miRNA as anti-cancer therapeutics will be presented.

Citation Format: Andrea L. Kasinski. To the tumor and beyond: Tales of a holistic miRNA delivery vehicle. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr PL05-02.
Supplementary Figure 1 from Procollagen Lysyl Hydroxylase 2 Is Essential for Hypoxia-Induced Breast Cancer Metastasis
Authors: Gilkes Daniele M. , Bajpai Saumendra , Wong Carmen C. , Chaturvedi Pallavi , Hubbi Maimon E. , Wirtz Denis , Semenza Gregg L.
Published: April 2023

PDF file - 98K, Figure S1. HIF-1α is required for PLOD induction under hypoxia in mouse embryo fibroblasts.
Supplementary Figure S6 from Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
Authors: Terai Hideki , Soejima Kenzo , Yasuda Hiroyuki , Nakayama Sohei , Hamamoto Junko , Arai Daisuke , Ishioka Kota , Ohgino Keiko , Ikemura Shinnosuke , Sato Takashi , Yoda Satoshi , Satomi Ryosuke , Naoki Katsuhiko , Betsuyaku Tomoko
Published: April 2023

Supplementary Figure S6 - PDF file 180K, A, B. Viability curves of PC9 GR cells (A) and PC9 gr1 cells (B) transfected with siRNA against FGFR1 (FGFR1 siRNA #1), FGFR3, or with the negative control mix at indicated concentrations of gefitinib. Representative data from three independent experiments are shown. Data represent the mean plus-minus SD. Values are expressed as mean plus-minus SD. *P<0.05, significant difference by Student's t test between control siRNA and FGFR1 siRNA #1 at 1microM gefitinib
Supplementary Tables 1 - 8 from Transcriptomes and shRNA Suppressors in a TP53 Allele–Specific Model of Early-Onset Colon Cancer in African Americans
Authors: Weige Charles C. , Birtwistle Marc R. , Mallick Himel , Yi Nengjun , Berrong Zuzana , Cloessner Emily , Duff Keely , Tidwell Josephine , Clendenning Megan , Wilkerson Brent , Farrell Christopher , Bunz Fred , Ji Hao , Shtutman Michael , Creek Kim E. , Banister Carolyn E. , Buckhaults Phillip J.
Published: April 2023

XLSX file - 5764K, S1. TP53 Codon 72 Polymorphism Genotype Frequency. S2. RNA-Seq Data. S3. TP53 Dependent Genes. S4. TP53 Codon 72 Dependent Genes. S5. Deep Sequencing. S6. TP53 Dependent shRNA. S7. Arg Dependent shRNA. S8. Pro Dependent shRNA.
Supplementary Figure 1 from RASSF1A-Mediated Regulation of AREG via the Hippo Pathway in Hepatocellular Carcinoma
Authors: Ahn Ei Yong , Kim Ji Su , Kim Gi Jeong , Park Young Nyun
Published: April 2023

PDF file - 1379K, Immunohistochemical analysis of nuclear and cytoplasmic YAP protein localization in human multistep hepatocarcinogenesis.
Supplementary Figure 5 from Comparative microRNA Profiling of Prostate Carcinomas with Increasing Tumor Stage by Deep Sequencing
Authors: Hart Martin , Nolte Elke , Wach Sven , Szczyrba Jaroslaw , Taubert Helge , Rau Tilman T. , Hartmann Arndt , Grässer Friedrich A. , Wullich Bernd
Published: April 2023

PDF file - 96K, Control experiments carried out in parallel. The individual control experiments shown in Figure 5A and 5B were carried out in parallel to show that the changes in growth behavior were not due to different cell culture conditions. We consistently observe a cytotoxic effect of the empty pSG5 vector on cell growth at the 72h time point.
Table S5 from CHCHD2 Is Coamplified with EGFR in NSCLC and Regulates Mitochondrial Function and Cell Migration
Authors: Wei Yuhong , Vellanki Ravi N. , Coyaud Étienne , Ignatchenko Vladimir , Li Lei , Krieger Jonathan R. , Taylor Paul , Tong Jiefei , Pham Nhu-An , Liu Geoffrey , Raught Brian , Wouters Bradly G. , Kislinger Thomas , Tsao Ming Sound , Moran Michael F.
Published: April 2023

Table S5. CHCHD2 interacting proteins identified by BioID
Table S4 from CHCHD2 Is Coamplified with EGFR in NSCLC and Regulates Mitochondrial Function and Cell Migration
Authors: Wei Yuhong , Vellanki Ravi N. , Coyaud Étienne , Ignatchenko Vladimir , Li Lei , Krieger Jonathan R. , Taylor Paul , Tong Jiefei , Pham Nhu-An , Liu Geoffrey , Raught Brian , Wouters Bradly G. , Kislinger Thomas , Tsao Ming Sound , Moran Michael F.
Published: April 2023

Table S4. CHCHD2 interacting proteins identified by AP-MS analysis of CHCHD2-Flag
Table S3 from CHCHD2 Is Coamplified with EGFR in NSCLC and Regulates Mitochondrial Function and Cell Migration
Authors: Wei Yuhong , Vellanki Ravi N. , Coyaud Étienne , Ignatchenko Vladimir , Li Lei , Krieger Jonathan R. , Taylor Paul , Tong Jiefei , Pham Nhu-An , Liu Geoffrey , Raught Brian , Wouters Bradly G. , Kislinger Thomas , Tsao Ming Sound , Moran Michael F.
Published: April 2023

Table S3. Proteins differentially expressed between CHCHD2 knockdown and control cells
Table S1 from CHCHD2 Is Coamplified with EGFR in NSCLC and Regulates Mitochondrial Function and Cell Migration
Authors: Wei Yuhong , Vellanki Ravi N. , Coyaud Étienne , Ignatchenko Vladimir , Li Lei , Krieger Jonathan R. , Taylor Paul , Tong Jiefei , Pham Nhu-An , Liu Geoffrey , Raught Brian , Wouters Bradly G. , Kislinger Thomas , Tsao Ming Sound , Moran Michael F.
Published: April 2023

Table S1. Xenografts, xenograft-derived cell lines and PCR primers used for CHCHD2 contructs
Figure S1 from miR-652 Promotes Tumor Proliferation and Metastasis by Targeting RORA in Endometrial Cancer
Authors: Sun Xiaomei , Dongol Samina , Qiu Chunping , Xu Ying , Sun Chenggong , Zhang Zhiwei , Yang Xingsheng , Zhang Qing , Kong Beihua
Published: April 2023

The relationship between miR-652 and estrogen
Supplemental Figure 1 from Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells
Authors: Hao Fang , Xu Qinhong , Zhao Yinglan , Stevens Jan V. , Young Steven H. , Sinnett-Smith James , Rozengurt Enrique
Published: April 2023

S1. The inhibition of PIP3 accumulation and YAP/TAZ-regulated gene expression in PDAC cells by the selective PI3K inhibitor A66 is dose dependent.
Data Supplement from GPER-Targeted, 99mTc-Labeled, Nonsteroidal Ligands Demonstrate Selective Tumor Imaging and In Vivo Estrogen Binding
Authors: Nayak Tapan K. , Ramesh Chinnasamy , Hathaway Helen J. , Norenberg Jeffrey P. , Arterburn Jeffrey B. , Prossnitz Eric R.
Published: April 2023

Figure S1: HPLC radiochromatograms of labeled compounds 5,6 and 8. Figure S2. HPLC radiochromatograms of urine and plasma from mouse injected with labeled compound 5. Table S1. Time-dependent biodistribution of labeled compound 5.
Supplementary Table 3 from BRAFV600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation
Authors: Silva Jillian M. , Bulman Christina , McMahon Martin
Published: April 2023

PDF file - 55K, Supplementary Table S3. Antibodies used for immunoblot analyses in this study.
Supplementary Figure Legends from BRAFV600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation
Authors: Silva Jillian M. , Bulman Christina , McMahon Martin
Published: April 2023

PDF file - 77K
Supplementary Figure 5 from Fhit Regulates EMT Targets through an EGFR/Src/ERK/Slug Signaling Axis in Human Bronchial Cells
Authors: Joannes Audrey , Grelet Simon , Duca Laurent , Gilles Christine , Kileztky Claire , Dalstein Véronique , Birembaut Philippe , Polette Myriam , Nawrocki-Raby Béatrice
Published: April 2023

PDF file - 117KB, Supplementary figure 5: Rescue of EGFR inhibition by active Src in Fhit siRNA-treated cells. (a) Western blot analysis of phospho-Src, total Src, Fhit and Slug levels in HBE4-E6/E7 cells transduced with control or Src. (b) Analysis by Western blotting and zymography of the effect of Src overexpression on vimentin and MMP-9 levels in Fhit siRNA transfectants treated with DMSO or gefitinib.
Supplementary Figure Legend from Angiopoietin-like Protein 2 Accelerates Carcinogenesis by Activating Chronic Inflammation and Oxidative Stress
Authors: Aoi Jun , Endo Motoyoshi , Kadomatsu Tsuyoshi , Miyata Keishi , Ogata Aki , Horiguchi Haruki , Odagiri Haruki , Masuda Tetsuro , Fukushima Satoshi , Jinnin Masatoshi , Hirakawa Satoshi , Sawa Tomohiro , Akaike Takaaki , Ihn Hironobu , Oike Yuichi
Published: April 2023

PDF file - 109K
Supplementary Figure 1 from Fhit Regulates EMT Targets through an EGFR/Src/ERK/Slug Signaling Axis in Human Bronchial Cells
Authors: Joannes Audrey , Grelet Simon , Duca Laurent , Gilles Christine , Kileztky Claire , Dalstein Véronique , Birembaut Philippe , Polette Myriam , Nawrocki-Raby Béatrice
Published: April 2023

PDF file - 99KB, Supplementary figure 1: Cell invasion induced by Fhit is Slug-dependent. (a) Analysis of the effect of Slug siRNA 2 or a scrambled siRNA on the invasive capacities of HBE4-E6/E7 transfectants in a modified Boyden chamber invasion assay. (b) Western blot and zymography analysis of the effect of Slug siRNA 2 or a scrambled siRNA on Fhit, Slug, vimentin and MMP-9 levels in HBE4-E6/E7 transfectants.
Supplementary Figure Legends from Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells
Authors: Lambert Arthur W. , Wong Chen Khuan , Ozturk Sait , Papageorgis Panagiotis , Raghunathan Rekha , Alekseyev Yuriy , Gower Adam C. , Reinhard Björn M. , Abdolmaleky Hamid M. , Thiagalingam Sam
Published: April 2023

This file contains figure legends for the supplementary data figures.
Supplementary Figure 3 from Contribution of Tumor Heterogeneity in a New Animal Model of CNS Tumors
Authors: Chen Fuyi , Becker Albert J. , LoTurco Joseph J.
Published: April 2023

PDF file - 1491K, Additional immunohistopathological features of ATRT like tumor induced by CAG-Ngn2 and PBCAG-HRasV12/AKT.
Supplementary Fig. S6 from Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells
Authors: Lambert Arthur W. , Wong Chen Khuan , Ozturk Sait , Papageorgis Panagiotis , Raghunathan Rekha , Alekseyev Yuriy , Gower Adam C. , Reinhard Björn M. , Abdolmaleky Hamid M. , Thiagalingam Sam
Published: April 2023

Gene sets repressed in SUM159 shPN cells
Supplementary Figure 1 from Contribution of Tumor Heterogeneity in a New Animal Model of CNS Tumors
Authors: Chen Fuyi , Becker Albert J. , LoTurco Joseph J.
Published: April 2023

PDF file - 1071K, Additional immunohistopathological features of GBM induced by PBCAG-HRasV12/AKT or PBGFAP-HRasV12/AKT.
Supplementary Fig. S4 from Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells
Authors: Lambert Arthur W. , Wong Chen Khuan , Ozturk Sait , Papageorgis Panagiotis , Raghunathan Rekha , Alekseyev Yuriy , Gower Adam C. , Reinhard Björn M. , Abdolmaleky Hamid M. , Thiagalingam Sam
Published: April 2023

Functional validation of POSTN and ITGB3 function using additional shRNA hairpins
Supplementary figures with legends from Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814
Authors: Sun Qing , Guo Yige , Liu Xiaohong , Czauderna Frank , Carr Michael I. , Zenke Frank T. , Blaukat Andree , Vassilev Lyubomir T.
Published: April 2023

Figure S1. Inhibition of DNA-PK activity by M3814 overactivates the p53 response to radiation-induced DSBs. Figure S2. The inactive M3814 enantiomer, M3814R, does not enhance the p53 response to IR and M3814. Figure S3. IR plus M3814 treatment induces different cell cycle responses in p53 wild-type and p53-deficient cancer cells. Figure S4. Irradiated p53 wild-type and p53-deficient cells respond differently to M3814. Figure S5. IR plus M3814 treatment induces premature senescence in p53 wild-type cancer cells. Figure S6. Analyses and functional validation of p53 knock-out clones. Figure S7. p53 determines the fate of A549 cancer cells exposed to IR and M3814. Figure S8. p53 is responsible for the strong cell cycle arrest in irradiated HT-1080 cells exposed to IR and M3814.
Supplementary Table 1 from Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis
Authors: de Queiroz Nina Marí Gual Pimenta , Xia Tianli , Konno Hiroyasu , Barber Glen N.
Published: April 2023

Ovarian cancer cell lines description
Supplementary Figure 3 from Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis
Authors: de Queiroz Nina Marí Gual Pimenta , Xia Tianli , Konno Hiroyasu , Barber Glen N.
Published: April 2023

HSV1Î"Î³34.5 infection after 5AZADC treatment in STING and/or cGAS deficient ovarian cancer cell lines.
Supplementary Figure 1 from Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis
Authors: de Queiroz Nina Marí Gual Pimenta , Xia Tianli , Konno Hiroyasu , Barber Glen N.
Published: April 2023

Demethylation treatment in cGAS deficient ovarian cancer cell lines.
Supplementary Table 1 from Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity
Authors: Aggarwal Rahul R. , Quigley David A. , Huang Jiaoti , Zhang Li , Beer Tomasz M. , Rettig Matthew B. , Reiter Rob E. , Gleave Martin E. , Thomas George V. , Foye Adam , Playdle Denise , Lloyd Paul , Chi Kim N. , Evans Christopher P. , Lara Primo N. , Feng Felix Y. , Alumkal Joshi J. , Small Eric J.
Published: April 2023

Supplementary Table 1. Clinical Characteristics of the Whole Genome Sequencing Cohort
Supplementary Methods from Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer
Authors: Nguyen Dan J.M. , Theodoropoulos George , Li Ying-Ying , Wu Chunjing , Sha Wei , Feun Lynn G. , Lampidis Theodore J. , Savaraj Niramol , Wangpaichitr Medhi
Published: April 2023

Primers and shIDO sequences.
Supplementary Figure 4 from Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer
Authors: Nguyen Dan J.M. , Theodoropoulos George , Li Ying-Ying , Wu Chunjing , Sha Wei , Feun Lynn G. , Lampidis Theodore J. , Savaraj Niramol , Wangpaichitr Medhi
Published: April 2023

Expression levels of TPH, IDO2 and TDO2.
Supplementary Tables 1-4 from Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells
Authors: Graham Mindy K. , Kim Jiyoung , Da Joseph , Brosnan-Cashman Jacqueline A. , Rizzo Anthony , Baena Del Valle Javier A. , Chia Lionel , Rubenstein Michael , Davis Christine , Zheng Qizhi , Cope Leslie , Considine Michael , Haffner Michael C. , De Marzo Angelo M. , Meeker Alan K. , Heaphy Christopher M.
Published: April 2023

Table S1. Sequences of oligonucleotides for CRISPR, telomere assays, and RT-qPCR. Table S2. Mean telomere lengths assessed from TRF southern blots of LAPC-4 EV and ATRXKO clones, and CWR22Rv1 EV and ATRXKO clones. Table S3. Microarray results of top 10 differentially expressed genes ranked by FDR adjusted P-value, comparing parental ATRX WT cell lines (LAPC-4 and CWR22Rv1) versus ATRXKO cell lines (LAPC-4 ATRXKO1-3 and CWR22Rv1 ATRXKO1-3). Table S4. Microarray results of top 10 differentially expressed genes with FDR adjusted P-value < 0.005 ranked by absolute fold-change, comparing LAPC-4 ATRXKO1-3 clones versus CWR22Rv1 ATRXKO1-3 clones.
Supplementary Figure 1 from Targeting the Kynurenine Pathway for the Treatment of Cisplatin-Resistant Lung Cancer
Authors: Nguyen Dan J.M. , Theodoropoulos George , Li Ying-Ying , Wu Chunjing , Sha Wei , Feun Lynn G. , Lampidis Theodore J. , Savaraj Niramol , Wangpaichitr Medhi
Published: April 2023

Increased OXPHOS was found in CR cells.
Table S1 from Epigenetic Reprogramming of Pericentromeric Satellite DNA in Premalignant and Malignant Lesions
Authors: Brückmann Nadine Heidi , Pedersen Christina Bøg , Ditzel Henrik Jørn , Gjerstorff Morten Frier
Published: April 2023

Staining and quantification of BMI1 and Pc bodies in nevi and melanoma tumors
Table S3:Primer sets used for site-directed mutagenesis to generate K108 and K440 aromatase mutants from Aromatase Acetylation Patterns and Altered Activity in Response to Sirtuin Inhibition
Authors: Molehin Deborah , Castro-Piedras Isabel , Sharma Monica , Sennoune Souad R. , Arena Daphne , Manna Pulak R. , Pruitt Kevin
Published: April 2023

Supplementary Table 3: Primer sets used in the generation of aromatase mutants during site directed mutagenesis.
Figure S2 from Epigenetic Reprogramming of Pericentromeric Satellite DNA in Premalignant and Malignant Lesions
Authors: Brückmann Nadine Heidi , Pedersen Christina Bøg , Ditzel Henrik Jørn , Gjerstorff Morten Frier
Published: April 2023

Staining of PRC1 subunits and Pc-related histone modifications in melanoma cells
Figure S2 from Aromatase Acetylation Patterns and Altered Activity in Response to Sirtuin Inhibition
Authors: Molehin Deborah , Castro-Piedras Isabel , Sharma Monica , Sennoune Souad R. , Arena Daphne , Manna Pulak R. , Pruitt Kevin
Published: April 2023

Aromatase peptides are acetylated in MCF-7 cells.
Supplemental Figure Legends from CDX1 Expression Induced by CagA-Expressing Helicobacter pylori Promotes Gastric Tumorigenesis
Authors: Choi Sang Il , Yoon Changhwan , Park Mi Ree , Lee DaHyung , Kook Myeong-Cherl , Lin Jian-Xian , Kang Jun Hyuk , Ashktorab Hassan , Smoot Duane T. , Yoon Sam S. , Cho Soo-Jeong
Published: April 2023

Supplementary Figure S1. Effect of H. pylori infection. Supplementary Figure S2. Suppression of CDX1 in gastric cancer cell lines. Supplementary Figure S3. Expression of CDX1 and stemness markers. Supplementary Figure S4. Effect of metformin on CDX1-expressing cells. Supplementary Figure S5. CDX1 suppression and the effect of chemotherapeutic agents.
Supplementary Figure 6 from Inhibition of the ATR–CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2
Authors: Koppenhafer Stacia L. , Goss Kelli L. , Terry William W. , Gordon David J.
Published: April 2023

Supplementary Figure 6 shows the effect of RRM2 knockdown in Ewing sarcoma cells, as well as RT-qPCR data for cells treated with AZD1775 and LY2603618.
Supplementary Figure 1 from Inhibition of the ATR–CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2
Authors: Koppenhafer Stacia L. , Goss Kelli L. , Terry William W. , Gordon David J.
Published: April 2023

Supplementary Figure 1 shows the effects of thymidine on cell cell synchronization and ATR/CHK1 inhibitors on DNA damage.
Supplementary Table 1 from Reactive Oxygen Species (ROS)-Inducing Triterpenoid Inhibits Rhabdomyosarcoma Cell and Tumor Growth through Targeting Sp Transcription Factors
Authors: Kasiappan Ravi , Jutooru Indira , Mohankumar Kumaravel , Karki Keshav , Lacey Alexandra , Safe Stephen
Published: April 2023

Antibodies.
Supplementary Table S1 from ABCC1-Exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1, Shortens Survival of Mice and Patients with Breast Cancer
Authors: Yamada Akimitsu , Nagahashi Masayuki , Aoyagi Tomoyoshi , Huang Wei-Ching , Lima Santiago , Hait Nitai C. , Maiti Aparna , Kida Kumiko , Terracina Krista P. , Miyazaki Hiroshi , Ishikawa Takashi , Endo Itaru , Waters Michael R. , Qi Qianya , Yan Li , Milstien Sheldon , Spiegel Sarah , Takabe Kazuaki
Published: April 2023

Patients' characteristics.
Figure S1 from Inhibition of Discoidin Domain Receptor 1 Prevents Stroma-Induced Peritoneal Metastasis in Gastric Carcinoma
Authors: Jin Hyejin , Ham In-Hye , Oh Hye Jeong , Bae Cheong A , Lee Dakeun , Kim Young-Bae , Son Sang-Yong , Chwae Yong-Joon , Han Sang-Uk , Brekken Rolf A. , Hur Hoon
Published: April 2023

A, Screening of DDR1 and mesenchymal cell marker (-SMA and Vimentin) expression. B, Genetic inhibition of DDR1 in GC cell line.
Supplementary Figure S3 from ABCC1-Exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1, Shortens Survival of Mice and Patients with Breast Cancer
Authors: Yamada Akimitsu , Nagahashi Masayuki , Aoyagi Tomoyoshi , Huang Wei-Ching , Lima Santiago , Hait Nitai C. , Maiti Aparna , Kida Kumiko , Terracina Krista P. , Miyazaki Hiroshi , Ishikawa Takashi , Endo Itaru , Waters Michael R. , Qi Qianya , Yan Li , Milstien Sheldon , Spiegel Sarah , Takabe Kazuaki
Published: April 2023

Intracellular ceramides of MCF7 cells with ABCC1 overexpression.
Table S4 from MCL1 and DEDD Promote Urothelial Carcinoma Progression
Authors: Hong Andrew L. , Guerriero Jennifer L. , Doshi Mihir B. , Kynnap Bryan D. , Kim Won Jun , Schinzel Anna C. , Modiste Rebecca , Schlauch Amy J. , Adam Rosalyn M. , Kwiatkowski David J. , Beroukhim Rameen , Letai Anthony , Rosenberg Jonathan E. , Hahn William C.
Published: April 2023

Sequences for arrayed RNAi vectors used
Supplementary Figure S1 from Potent Antineoplastic Effects of Combined PI3Kα–MNK Inhibition in Medulloblastoma
Authors: Eckerdt Frank , Bell Jonathan B. , Beauchamp Elspeth M. , Clymer Jessica , Blyth Gavin T. , Kosciuczuk Ewa M. , Ma Quanhong , Chen David Z. , Horbinski Craig , Goldman Stewart , Munshi Hidayatullah G. , Hashizume Rintaro , Platanias Leonidas C.
Published: April 2023

Body weight of mice from flank tumor xenograft experiment
Supplementary Figures 1-5 from Cancer Stem Cell Phenotypes in ER+ Breast Cancer Models Are Promoted by PELP1/AIB1 Complexes
Authors: Truong Thu H. , Hu Hsiangyu , Temiz Nuri A. , Hagen Kyla M. , Girard Brian J. , Brady Nicholas J. , Schwertfeger Kathryn L. , Lange Carol A. , Ostrander Julie H.
Published: April 2023

Supplementary Western Blots and RNA expression for PELP1, Western blot controls for fractionation, Kaplan Meier plots, soft agar assay images, and ALDH flow cytometry plots.
Table S2 from Pattern-Specific Transcriptomics Identifies ASGR2 as a Predictor of Hematogenous Recurrence of Gastric Cancer
Authors: Tanaka Haruyoshi , Kanda Mitsuro , Miwa Takashi , Tanaka Chie , Kobayashi Daisuke , Umeda Shinichi , Shibata Masahiro , Suenaga Masaya , Hattori Norifumi , Hayashi Masamichi , Iwata Naoki , Yamada Suguru , Nakayama Goro , Fujiwara Michitaka , Kodera Yasuhiro
Published: April 2023

Correlation of clinicopathological factors and ASGR2 expression levels
Supplementary Figure S2 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
Authors: Hernández-Prat Anna , Rodriguez-Vida Alejo , Juanpere-Rodero Nuria , Arpi Oriol , Menéndez Silvia , Soria-Jiménez Luis , Martínez Alejandro , Iarchouk Natalia , Rojo Federico , Albanell Joan , Brake Rachael , Rovira Ana , Bellmunt Joaquim
Published: April 2023

Molecular effects of everolimus on the PI3K/mTOR signaling pathway on bladder cancer cells in vitro.
Supplementary Figure S1 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
Authors: Hernández-Prat Anna , Rodriguez-Vida Alejo , Juanpere-Rodero Nuria , Arpi Oriol , Menéndez Silvia , Soria-Jiménez Luis , Martínez Alejandro , Iarchouk Natalia , Rojo Federico , Albanell Joan , Brake Rachael , Rovira Ana , Bellmunt Joaquim
Published: April 2023

Cellular effects of TAK-228 on human bladder cancer cell lines.
Figure S5 from Pattern-Specific Transcriptomics Identifies ASGR2 as a Predictor of Hematogenous Recurrence of Gastric Cancer
Authors: Tanaka Haruyoshi , Kanda Mitsuro , Miwa Takashi , Tanaka Chie , Kobayashi Daisuke , Umeda Shinichi , Shibata Masahiro , Suenaga Masaya , Hattori Norifumi , Hayashi Masamichi , Iwata Naoki , Yamada Suguru , Nakayama Goro , Fujiwara Michitaka , Kodera Yasuhiro
Published: April 2023

Public database analyses